Challenges in the development of an HIV-1 vaccine

Nature

Volumn 455, Issue 7213, 2008, Pages 613-619

  Barouch, Dan H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS VACCINE; VIRUS VECTOR;

DISEASE TREATMENT; HEALTH CARE; HOMINID; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; VACCINE;

CELLULAR IMMUNITY; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; GENE DELIVERY SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 53349160053     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature07352     Document Type: Review

References (93)

1. Barre-Sinoussi, F. et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868-871 (1983).
2. Gallo, R. C. et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224, 500-503 (1984).
3. Popovic, M., Sarngadharan, M. G., Read, E. & Gallo, R. C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224, 497-500 (1984).
4. Sarngadharan, M. G., Popovic, M., Bruch, L., Schupbach, J. & Gallo, R. C. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science 224, 506-508 (1984).
5. Schupbach, J. et al. Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS. Science 224, 503-505 (1984).
6. Fauci, A. S. 25 years of HIV. Nature 453, 289-290 (2008).
7. Quinn, T. C. et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N. Engl. J. Med. 342, 921-929 (2000).
8. Mascola, J. R. et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J. Infect. Dis. 173, 340-348 (1996).
9. Moore, J. P. et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69, 101-109 (1995).
10. Flynn, N. M. et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191, 654-665 (2005).
11. Pitisuttithum, P. et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661-1671 (2006).
12. Priddy, F. H. et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin. Infect. Dis. 46, 1769-1781 (2008).
13. Fauci, A. S. The release of new data from the HVTN 502 (STEP) HIV vaccine study. NIH News 〈http://www3.niaid.nih.gov/about/directors/news/ step_11707.htm〉 (2007). These data demonstrate that a homologous rAd5-Gag/Pol/Nef vaccine regimen did not protect against HIV-1 in humans and may have increased risk of HIV-1 acquisition in individuals with pre-existing Ad5-specific neutralizing antibodies.
14. Gaschen, B. et al. Diversity considerations in HIV-1 vaccine selection. Science 296, 2354-2360 (2002).
15. Walker, B. D. & Korber, B. T. Immune control of HIV: the obstacles of HLA and viral diversity. Nature Immunol. 2, 473-475 (2001).
16. Montefiori, D., Sattentau, Q., Flores, J., Esparza, J. & Mascola, J. Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med. 4, e348 (2007).
17. Kwong, P. D. et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659 (1998).
18. Wyatt, R. et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393, 705-711 (1998).
19. Chen, B. et al. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433, 834-841 (2005).
20. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
21. Richman, D. D., Wrin, T., Little, S. J. & Petropoulos, C. J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl Acad. Sci. USA 100, 4144-4149 (2003).
22. Li, Y. et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nature Med. 13, 1032-1034 (2007).
23. Zhou, T. et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445, 732-737 (2007).
24. Haynes, B. F. et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308, 1906-1908 (2005).
25. Sun, Z. Y. et al. HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane. Immunity 28, 52-63 (2008).
26. Frey, G. et al. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc. Natl Acad. Sci. USA 105, 3739-3744 (2008).
27. Baba, T. W. et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nature Med. 6, 200-206 (2000).
28. Mascola, J. R. et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Med. 6, 207-210 (2000).
29. + T cells with a predominant V beta usage during the primary immune response to HIV. Nature 370, 463-467 (1994).
30. Koup, R. A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650-4655 (1994).
31. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68, 6103-6110 (1994).
32. Musey, L. et al. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N. Engl. J. Med. 337, 1267-1274 (1997).
33. Kiepiela, P. et al. Dominant influence of HLA-B in mediating the potential coevolution of HIV and HLA. Nature 432, 769-775 (2004).
34. + T-cell responses to different HIV proteins have discordant associations with viral load. Nature Med. 13, 46-53 (2007).
35. + lymphocytes. Science 283, 857-860 (1999).
36. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189, 991-998 (1999).
37. Phillips, R. E. et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354, 453-459 (1991).
38. Allen, T. M. et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407, 386-390 (2000).
39. Barouch, D. H. et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415, 335-339 (2002).
40. + T cells. Blood 107, 4781-4789 (2006).
41. + T cell responses. J. Exp. Med. 204, 1405-1416 (2007).
42. Darrah, P. A. et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nature Med. 13, 843-850 (2007).
43. Watkins, D. I., Burton, D. R., Kallas, E. G., Moore, J. P. & Koff, W. C. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nature Med. 14, 617-621 (2008).
44. Seder, R. A., Darrah, P. A. & Roederer, M. T-cell quality in memory and protection: implications for vaccine design. Nature Rev. Immunol. 8, 247-258 (2008).
45. Chun, T. W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183-188 (1997).
46. + T cells during primary HIV-1 infection. Proc. Natl Acad. Sci. USA 95, 8869-8873 (1998).
47. + T cells. Nature 417, 95-98 (2002).
48. + T cell depletion and viral replication in SIV infection. Science 280, 427-431 (1998).
49. + T cells in multiple tissues during acute SIV infection. Nature 434, 1093-1097 (2005).
50. + T cells. Nature 434, 1148-1152 (2005).
51. Brenchley, J. M. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Med. 12, 1365-1371 (2006).
52. Mattapallil, J. J. et al. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J. Exp. Med. 203, 1533-1541 (2006).
53. Daniel, M. D., Kirchhoff, F., Czajak, S. C., Sehgal, P. K. & Desrosiers, R. C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258, 1938-1941 (1992).
54. Wyand, M. S., Manson, K. H., Garcia-Moll, M., Montefiori, D. & Desrosiers, R. C. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70, 3724-3733 (1996).
55. Learmont, J. C. et al. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N. Engl. J. Med. 340, 1715-1722 (1999).
56. Baba, T. W. et al. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267, 1820-1825 (1995).
57. Baba, T. W. et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nature Med. 5, 194-203 (1999).
58. Murphey-Corb, M. et al. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 246, 1293-1297 (1989).
59. + T cell responses in nonhuman primates. Proc. Natl Acad. Sci. USA 102, 15190-15194 (2005).
60. Wille-Reece, U. et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 203, 1249-1258 (2006).
61. Casimiro, D. R. et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77, 6305-6313 (2003).
62. Graham, B. S. et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J. Infect. Dis. 194, 1650-1660 (2006).
63. Barouch, D. H. et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486-492 (2000).
64. Chong, S. Y. et al. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Vaccine 25, 4967-4982 (2007).
65. Luckay, A. et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J. Virol. 81, 5257-5269 (2007).
66. Liu, J., Kjeken, R., Mathiesen, I. & Barouch, D. H. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J. Virol. 82, 5643-5649 (2008).
67. Shiver, J. W. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335 (2002).
68. Catanzaro, A. T. et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis. 194, 1638-1649 (2006).
69. Amara, R. R. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69-74 (2001).
70. Harari, A. et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 205, 63-77 (2008).
71. Shiver, J. W. & Emini, E. A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 55, 355-372 (2004).
72. MAC239 challenges in rhesus monkeys.
73. Mothe, B. R. et al. Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J. Virol. 77, 2736-2740 (2003).
74. Pal, R. et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J. Virol. 76, 292-302 (2002).
75. Zhang, Z. Q. et al. Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. J. Virol. 76, 12845-12854 (2002).
76. Wilson, N. A. et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J. Virol. 80, 5875-5885 (2006).
77. + central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312, 1530-1533 (2006).
78. Vogels, R. et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77, 8263-8271 (2003).
79. Abbink, P. et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81, 4654-4663 (2007).
80. Thorner, A. R. et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J. Clin. Microbiol. 44, 3781-3783 (2006).
81. Kostense, S. et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18, 1213-1216 (2004).
82. Fauci, A. S. et al. HIV vaccine research: the way forward. Science 321, 530-532 (2008). This perspective describes revised NIH research priorities for HIV-1 vaccine research.
83. Catanzaro, A. T. et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 25, 4085-4092 (2007).
84. Fauci, A. S. NIAID will not move forward with the PAVE 100 HIV vaccine trial. NIH News 〈http://www3.niaid.nih.gov/news/newsreleases/2008/ pave100.htm〉 (2008).
85. Barouch, D. H. et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172, 6290-6297 (2004).
86. Roberts, D. M. et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441, 239-243 (2006).
87. Farina, S. F. et al. Replication-defective vector based on a chimpanzee adenovirus. J. Virol. 75, 11603-11613 (2001).
88. Fitzgerald, J. C. et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol. 170, 1416-1422 (2003).
89. Liu, J. et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J. Virol. 82, 4844-4852 (2008).
90. Barouch, D. H. Novel adenovirus vector-based vaccines for HIV-1. Keystone Symposia on HIV Vaccines, Banff, Canada. Abstract X7 009, page 60 (Keystone Symposia, 27 March-1 April 2008).
91. Liao, H. X. et al. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353, 268-282 (2006).
92. Weaver, E. A. et al. Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. J. Virol. 80, 6745-6756 (2006).
93. Fischer, W. et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nature Med. 13, 100-106 (2007). This manuscript proposes the use of polyvalent 'mosaic' antigens to improve immunologic coverage of global HIV-1 diversity.